Image

Timely Interventions to Enable and Reach Patients With Heart Failure, and Their Caregivers With Palliative Care

Timely Interventions to Enable and Reach Patients With Heart Failure, and Their Caregivers With Palliative Care

Recruiting
21-99 years
All
Phase N/A

Powered by AI

Overview

There is evidence for the effectiveness and feasibility of the individual components of TIER-HF-PC, however there is a need to test how these individual components interact to allow the researchers to deliver TIER-HF-PC as a model of care in its totality. In the short term, this study will assess if TIER-HF-PC is beneficial for patients and caregivers.

Description

Timely Interventions to Enable and Reach patients with Heart Failure, and their caregivers with Palliative Care, or TIER-HF-PC, is a novel model of palliative care, designed to address gaps of palliative care delivery for patients with advanced heart failure, and their caregivers.

TIER-HF-PC is a service, led by a palliative care nurse, with support by a palliative care physician. This nurse will actively screen and monitor patients for problems, and then match the type and intensity of palliative care treatments to the severity of problems reported. The nurse will also facilitate processes for patients to initiate contact with health care providers should problems arise. This decreases the overall burden on palliative care services, enabling a scalable and more cost-effective model of care for a larger number of patients. The service will also utilize a proactive approach to care, increasing self-care skills and understanding of disease and treatment options. Earlier palliative care support will enable problems to be managed actively before they escalate into crises.

Overall aim: To test the effectiveness and implementation of the interacting components of TIER-HF-PC.

Specific aim 1a: To evaluate the impact of TIER-HF-PC on patients. The primary outcome is patient quality-of-life at 24 weeks, measured on the Kansas City Cardiomyopathy Questionnaire. Secondary outcomes include patient anxiety, depression, coping, spirituality, healthcare utilization, survival, and cost-effectiveness of TIER-HF-PC.

Specific aim 1b: To evaluate the impact of TIER-HF-PC on caregivers. Outcomes evaluated include caregiver quality-of-life.

  • Hypothesis 1: The researchers hypothesize that TIER-HF-PC will be superior to usual care, in improving patient and caregiver quality-of-life.

Specific aim 2: To evaluate the implementation outcomes of TIER-HF-PC.

  • Hypothesis 2: The researchers hypothesize that participants will be satisfied with the TIER-HF-PC service, though modifications might be needed for fine-tuning of the appropriateness and timeliness of care provision in TIER-HF-PC. They will evaluate these implementation outcomes through a validated service evaluation survey and semi-structured interviews. Fidelity to study protocols will be assessed through audits of case notes and study processes.

Eligibility

Inclusion Criteria:

  • Patients:
    1. 21 years or older and
    2. able to communicate in English or Chinese and
    3. be of stage C or D heart failure, as defined by American College of Cardiology/American Heart Association (ACC/AHA) classification system and
    4. have functional limitation of New York Heart Association (NYHA) functional status of at least 2 or more and
    5. be deemed by their cardiologist's clinical judgement to have an expected prognosis of at least 6 months survival, and
    6. have had a heart failure related hospitalization event (e.g. symptomatic decompensated heart failure) within 6 months prior to recruitment and
    7. have a phone that allows telecommunication.
  • Caregivers must meet all the following inclusion criteria to be eligible for the

    study :

    • direct, unpaid, family caregiver of the patient;
    • self-reported by the patient to be the main person to be either:
    • responsible for up to 4 hours a day of caregiving tasks
    • and/or decision maker/spokesperson with the medical team
    • Caregiver may or may not live in the same residence as the patient.
    • Caregivers must be 21 years and above.
    • Able to communicate in English or Chinese.

Exclusion Criteria:

  • Patients:
    1. have cognitive impairment (e.g., dementia)
    2. have severe, untreated, active mental illness (e.g., major depressive disorder)
    3. have ventricular assist device implant.
    4. have non-reversible hearing or visual loss or
    5. are active drug abuser or
    6. already known to a palliative care service.
  • Caregivers who meet any of the exclusion criteria at baseline will be ineligible for

    the study:

    • have cognitive impairment (e.g., dementia) or
    • have severe, untreated, active mental illness (e.g., major depressive disorder)
    • have non-reversible hearing or visual loss.
    • are active drug abuser or
    • are a domestic helper for the patient

Study details
    Heart Failure

NCT06244953

National Cancer Centre, Singapore

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.